Immunic Therapeutics has been granted a new patent in Europe covering multiple dosing regimens of its experimental therapy vidofludimus calcium and related molecules for multiple sclerosis (MS) and other indications. The patent, titled “Dosage Regimen of Vidofludimus for Use in the Treatment of a Chronic Inflammatory and/or Autoimmune Diseases,” covers all relevant dosing regimens of […]
The post New European patent covers all dosing regimens of experimental MS therapy appeared first on Multiple Sclerosis News Today.
Source: multiplesclerosisnewstoday.com